A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.
The study by health economics and public health researchers at the University of California at Berkeley found that prices paid in 2019 by Blue Cross Blue Shield health plans in hospital outpatient departments were double those paid in physician offices for biologics, chemotherapies, and other infused cancer drugs (99–104% higher) and for infused hormonal therapies (68% higher).
A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
